Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07047209 · ClinicalTrials.gov registry record · Phase 2
Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of ALS (Amyotrophic Lateral Sclerosis), sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT07047209: Active Phase 2 study of ALS (Amyotrophic Lateral Sclerosis), sponsored by Massachusetts General Hospital.
NCT07047209 is a Phase 2 study of ALS (Amyotrophic Lateral Sclerosis) that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 361-participant average among 6 other ALS (Amyotrophic Lateral Sclerosis) trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07047209, a Phase 2 study of ALS (Amyotrophic Lateral Sclerosis), is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.
Primary Outcome
Safety: Defined as the occurrence of serious and non-serious treatment-emergent adverse events (TEAEs) and clinically significant treatment-emergent abnormalities in clinical and laboratory values including digoxin trough levels, in ALS individuals treated with study treatment.
Conditions Studied
Interventions
- DRUG Digoxin
Study Locations (3)
Florida
- Nova Southeastern University - Davie
Illinois
- Northwestern Universsity - Chicago
Massachusetts
- MGH - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT07047209 still lists
NCT07047209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 361-participant average among 6 other ALS (Amyotrophic Lateral Sclerosis) trials with a reported enrollment target (89% lower).
The record links to 1 condition, with ALS (Amyotrophic Lateral Sclerosis) appearing as the primary indexed condition, and to 1 intervention - of which Digoxin is the first listed.
NCT07047209 reports a single indexed study location in Florida, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07047209 about?
NCT07047209 is a clinical study titled "Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)". This clinical trial is being conducted to learn about safety and tolerability of digoxin in ALS individuals. Additionally, this trial aims to better understand if digoxin has an effect on slowing neurodegeneration in ALS.
What is the current status of trial NCT07047209?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-05-27. Estimated completion is 2026-04.
What conditions does trial NCT07047209 study?
This clinical trial studies the following conditions: ALS (Amyotrophic Lateral Sclerosis).
What interventions are being tested in trial NCT07047209?
The interventions under investigation include: Digoxin (DRUG).
Who is sponsoring clinical trial NCT07047209?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07047209 being conducted?
This trial has 3 study locations across Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ALS (Amyotrophic Lateral Sclerosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tofersen in Non-SOD1 ALS
RECRUITING · Phase 2
-
Clinical Outcome Assessment for AT & BCI
RECRUITING · NA
-
ALS Research Collaborative
RECRUITING
-
Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS
RECRUITING · NA
-
Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study
RECRUITING · NA
-
Obi Medical Robot: Evaluating Effectiveness Related to Usability
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI